Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 5/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21616869 | 0.97 | TSHR (0.50) | TSHRFAAHTRPV1PPARA | |
| SCHEMBL5074183 | 0.97 | TSHR (0.50) | TSHRFAAHTRPV1PPARA | |
| SCHEMBL322670 | 0.97 | TSHR (0.50) | TSHRFAAHTRPV1PPARA | |
| SCHEMBL7860226 | 0.97 | TSHR (0.50) | TSHRFAAHTRPV1PPARA | |
| SCHEMBL1678870 | 0.92 | — | — | |
| SCHEMBL3034952 | 0.79 | TSHR (0.46) | TSHRFAAHTRPV1PPARAALDH1A1 | |
| SCHEMBL266229 | 0.77 | TSHR (0.44) | TSHRFAAHTRPV1PPARA | |
| SCHEMBL700497 | 0.75 | TSHR (0.48) | TSHRFAAHTRPV1PPARA | |
| SCHEMBL699652 | 0.75 | TSHR (0.48) | TSHRFAAHTRPV1PPARA | |
| SCHEMBL3033922 | 0.75 | ALDH1A1 (0.43) | TSHRFAAHTRPV1PPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185302-B1 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | GENENCOR INT (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8431121-B2 | Specifically targeted catalytic antagonists and uses thereof | DANISCO US INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110262419-A1 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | DANISCO US, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | ISHIBASHI MICHIO (JP) | 2005-06-30 | — | — | US | disclosed |
| US-6878745-B2 | Selective preventives/remedies for progressive lesions after organ damage | Ishibashi, Michio (JP) | 2005-04-12 | — | — | US | disclosed |
| US-20040170618-A1 | antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. | DAVIS BENJAMIN G (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | ISHIBASHI, MICHIO (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1277747-A1 | SELECTIVE PREVENTIVES/REMEDIES FOR PROGRESSIVE LESIONS AFTER ORGAN DAMAGE | Ishibashi, Michio (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-1185302-A2 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | GENENCOR INTERNATIONAL, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000064485-A9 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | GENENCOR INT (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2000064485-A2 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | GENENCOR INTERNATIONAL, INC. (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | CCL11, CD68, CCL2 | TSHR 3380/4885FAAH 2777/4885TRPV1 1237/4885 |
| US-20110262419-A1 | SPECIFICALLY TARGETED CATALYTIC ANTAGONISTS AND USES THEREOF | ENGASE, GAA, DNPEP | TSHR 1053/4885FAAH 436/4885TRPV1 2423/4885 |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | TSHR 594/4885FAAH 2718/4885TRPV1 3360/4885 |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | CD68, MSR1, CCL2 | TSHR 3555/4885FAAH 1761/4885TRPV1 864/4885 |
| US-20040170618-A1 | antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. | ENGASE, GPR84, ADGRF1 | TSHR 516/4885FAAH 484/4885TRPV1 1842/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | TSHR 47/4885FAAH 1410/4885TRPV1 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.